Cardiac amyloidosis – Diagnostics – Overview of Information and Clinical Research

Cardiac amyloidosis is a condition where misshapen proteins build up in the heart muscle, making it stiff and thick. While it was once rarely diagnosed, improved testing methods and greater awareness among doctors have made it easier to identify. Early detection matters because treatments are now available that can slow the disease and improve quality of life.

Introduction: Who Should Undergo Diagnostics

If you experience symptoms that might point to heart problems, it’s important to see a healthcare provider. Cardiac amyloidosis often causes symptoms similar to heart failure, which means many people don’t realize what they’re dealing with at first. You might notice shortness of breath when you’re active or even when you’re resting. Swelling in your belly, legs, or feet is another common sign. Extreme tiredness that lasts for days, heart palpitations during your normal daily activities, or feeling dizzy when you change positions can also signal a problem.^[1]

Sometimes the condition affects other parts of your body beyond the heart. You may experience tingling or numbness in your hands or feet, a condition called peripheral neuropathy, which happens when nerves are damaged by protein deposits. Some people have trouble with their digestive system, experiencing diarrhea, nausea, or unexplained weight loss. Others notice strange symptoms like purple spots around their eyelids, easy bruising, or even changes in their tongue, which can appear larger than normal.^[19]

Certain groups of people face higher risk and should be especially watchful. Older adults are more likely to develop cardiac amyloidosis, particularly a type called wild-type transthyretin amyloidosis. People of Caribbean and African descent may also have higher risk. If you have a family history of the condition, this is particularly important because some forms of cardiac amyloidosis are hereditary, meaning they run in families due to genetic changes.^[19]

Your doctor might also recommend testing if you have certain heart-related findings that serve as red flags. These include atrial fibrillation, which is an irregular heart rhythm, or unusual thickening of the wall of your left ventricle, the heart’s main pumping chamber. Problems with your heart’s electrical conduction system or elevated levels of certain proteins in your blood that signal heart damage may also prompt further investigation.^[1]

⚠️ Important

Cardiac amyloidosis is frequently missed or diagnosed late because its symptoms overlap with more common heart conditions. If you have unexplained heart failure symptoms, especially if you also have nerve problems, digestive issues, or a family history of the disease, don’t hesitate to ask your doctor about testing for cardiac amyloidosis. Early diagnosis can make a significant difference in your treatment options and outcomes.

Diagnostic Methods to Identify the Disease

Diagnosing cardiac amyloidosis requires a thorough approach because it’s a systemic disease, meaning it affects your whole body, not just your heart. Your healthcare provider will start by listening to your symptoms, reviewing your medical history, and conducting a physical examination. These initial steps help determine whether further testing is needed.^[1]

Blood and urine tests are among the first diagnostic tools your doctor will use. These tests look for abnormal proteins called amyloid proteins, as well as markers that show how well your heart is functioning. In particular, doctors check for elevated levels of certain cardiac biomarkers that indicate heart stress or damage. They also perform tests to look for specific types of light chains, which are protein fragments that can form amyloid deposits in AL amyloidosis.^[9]

An electrocardiogram, or EKG, is a simple test that records your heart’s electrical activity. It shows patterns that might suggest cardiac amyloidosis, such as low voltage readings or abnormal rhythms. This test is painless and involves placing small electrodes on your chest to measure the electrical signals your heart produces with each beat.^[1]

Imaging tests provide detailed pictures of your heart and help doctors see whether protein deposits have thickened your heart muscle. An echocardiogram uses sound waves to create moving images of your heart. A special type called an echocardiogram with strain can reveal subtle changes in how your heart muscle moves and squeezes, which is particularly helpful in detecting cardiac amyloidosis. Doctors look for signs like a sparkling or granular appearance of the heart tissue on the images.^[9]

A cardiac MRI, or magnetic resonance imaging scan of the heart, provides even more detailed pictures. This test uses powerful magnets and radio waves to create three-dimensional images of your heart. It’s especially useful for distinguishing cardiac amyloidosis from other conditions that cause the heart muscle to thicken, such as high blood pressure or other forms of cardiomyopathy, which is a general term for heart muscle disease.^[1]

Nuclear imaging tests, sometimes called “amyloid scans,” are another important diagnostic tool. These tests involve injecting a small amount of radioactive material into your bloodstream. Special cameras then detect where this material accumulates in your body. For certain types of cardiac amyloidosis, particularly transthyretin amyloidosis, these scans can show protein buildup in the heart without requiring a biopsy.^[9]

A biopsy is a procedure where doctors take a small sample of tissue to examine under a microscope. This can be done from various parts of your body, including your heart, fat tissue under your skin, bone marrow, or other organs. The tissue is then tested to confirm the presence of amyloid deposits and determine what type of protein is causing them. A technique called mass spectrometry helps identify the specific protein involved, which is crucial because different types of amyloidosis require different treatments.^[7]

Genetic testing may be recommended if doctors suspect a hereditary form of cardiac amyloidosis. This involves analyzing your DNA to look for genetic changes or mutations that can cause the body to produce abnormal transthyretin proteins. If a genetic mutation is found, your family members may also be offered testing and screening, as they could be at risk of developing the condition.^[1]

Your healthcare provider will likely use a combination of these tests rather than relying on just one. Because cardiac amyloidosis can affect multiple organs, doctors take a comprehensive approach, looking at your heart while also checking for symptoms elsewhere in your body. This big-picture view helps ensure an accurate diagnosis and appropriate treatment plan.^[2]

⚠️ Important

Getting an accurate diagnosis requires determining not only whether you have cardiac amyloidosis, but also which type you have. Light-chain amyloidosis and transthyretin amyloidosis require completely different treatments, so proper identification through tissue analysis and specialized testing is essential. Make sure your tissue samples are examined by experts experienced in diagnosing amyloidosis.

Diagnostics for Clinical Trial Qualification

When patients with cardiac amyloidosis are being considered for clinical trials, they typically undergo a more extensive set of diagnostic tests beyond those used for standard diagnosis. Clinical trials are research studies that test new treatments or approaches to managing the disease. To participate, patients must meet specific criteria that ensure the study results will be meaningful and that participants are suitable for the experimental treatment being tested.^[13]

Blood tests are commonly required to assess your overall health and how well your organs are functioning. These tests measure various markers including kidney function, liver function, and levels of specific proteins related to cardiac amyloidosis. Cardiac biomarkers that indicate heart damage or stress are also closely monitored. Some trials specifically look at light chain levels in patients with AL amyloidosis to determine disease severity and track response to treatment.^[10]

Imaging tests play a central role in determining eligibility for clinical trials. Echocardiograms with specialized techniques like strain imaging help measure how well your heart is pumping and how thick your heart walls have become. These measurements must often fall within certain ranges for you to qualify for a trial. Cardiac MRI scans may be used to provide detailed information about the extent of amyloid infiltration in your heart and to measure specific features like ejection fraction, which indicates how much blood your heart pumps with each beat.^[5]

Nuclear imaging studies, particularly bone scintigraphy scans, are sometimes used in clinical trials focusing on transthyretin amyloidosis. These scans help confirm the diagnosis without requiring a heart biopsy and can also provide baseline measurements of disease severity that researchers track throughout the study.^[10]

Tissue typing and genetic testing are often required to confirm which specific type of cardiac amyloidosis you have. For trials testing treatments for hereditary transthyretin amyloidosis, genetic testing must confirm the presence of a TTR gene mutation. For AL amyloidosis trials, doctors need to verify through biopsy and special staining techniques that light chains are causing your amyloid deposits.^[2]

Functional assessments help researchers understand how the disease affects your daily life and whether treatments make a difference. You might be asked to complete questionnaires about your symptoms and quality of life. Physical tests such as a six-minute walk test, where you walk as far as you can in six minutes, measure your exercise capacity and can be used to track whether treatment helps you become more active.^[18]

Clinical trials often require repeat testing throughout the study period to monitor how you respond to treatment. This means you may need to have blood tests, imaging scans, and other assessments at regular intervals. These repeated measurements help researchers determine whether the experimental treatment is working and whether it’s safe. The frequency and type of testing will depend on the specific trial and what’s being studied.^[8]

Some trials have strict inclusion and exclusion criteria based on disease stage. For example, some studies only accept patients with early-stage disease, while others focus on those with more advanced symptoms. Your doctor will review the specific requirements of available clinical trials to determine which ones you might be eligible for based on your diagnostic test results.^[13]

Prognosis and Survival Rate

Prognosis

The outlook for people with cardiac amyloidosis depends on several factors, including which type of amyloidosis you have, how advanced the disease is when diagnosed, and how well you respond to treatment. In the past, cardiac amyloidosis was considered essentially untreatable with a poor prognosis. Today, the picture has changed dramatically thanks to new therapies and earlier diagnosis.^[18]

The type of amyloidosis makes a significant difference in prognosis. Light-chain amyloidosis generally has a more serious outlook because it tends to progress more rapidly. This form can affect multiple organs in addition to the heart, which complicates treatment. Transthyretin amyloidosis typically follows a slower course, particularly the wild-type form that occurs in older adults. With proper treatment, many patients with transthyretin amyloidosis can maintain good quality of life for years.^[2]

How early the disease is caught plays a crucial role in determining outcomes. When cardiac amyloidosis is diagnosed before significant heart damage occurs, treatments are more effective at slowing disease progression. Early diagnosis also means patients can start disease-modifying therapies sooner, which can prevent or delay complications like heart failure and dangerous heart rhythms. This is why increased awareness among doctors about cardiac amyloidosis symptoms has become so important.^[13]

The availability of new treatments has significantly improved the prognosis for many patients. For transthyretin amyloidosis, medications that stabilize the transthyretin protein or reduce its production can slow the buildup of amyloid deposits. These therapies have been shown to reduce disease progression and improve survival. For light-chain amyloidosis, advances in chemotherapy and immunotherapy have helped many patients achieve better control of their disease.^[8]

Individual factors also influence prognosis. Your overall health, the presence of other medical conditions, and how well your organs are functioning all play a role. Patients who develop complications like severe heart failure, kidney problems, or dangerous heart rhythms generally have more challenging outlooks. However, even these complications can often be managed with appropriate medical care and, in some cases, advanced interventions like implantable devices or organ transplantation.^[18]

Your response to treatment is perhaps the most important factor in determining long-term prognosis. Some patients respond very well to disease-modifying therapies, with stabilization or even improvement in heart function. Others may have a more limited response. Regular monitoring with your healthcare team allows for adjustments in treatment strategy to optimize outcomes.^[1]

Survival Rate

Survival rates for cardiac amyloidosis have improved substantially in recent years, but they still vary widely depending on disease type and treatment. For light-chain amyloidosis affecting the heart, the condition remains serious. However, modern chemotherapy and immunotherapy approaches have extended survival times compared to what was possible even a decade ago. Patients who achieve a good response to treatment, meaning their abnormal light chain levels drop significantly, tend to have much better survival outcomes.^[8]

For transthyretin amyloidosis, the introduction of disease-modifying therapies has been a game-changer. Studies of medications that stabilize or reduce transthyretin protein production have shown meaningful improvements in survival rates. Many patients with transthyretin cardiac amyloidosis can now live for several years or more with good quality of life, particularly when treatment is started early in the disease course.^[12]

The stage of disease at diagnosis significantly impacts survival statistics. Patients diagnosed at earlier stages, before extensive heart damage has occurred, generally have better survival rates than those diagnosed with advanced disease. This underscores the importance of recognizing symptoms early and seeking medical evaluation promptly.^[18]

It’s important to remember that survival statistics are based on groups of patients and provide general information. Individual experiences can vary greatly. Your own outlook depends on your unique situation, including your specific type of amyloidosis, overall health, response to treatment, and many other factors. Your healthcare team is best positioned to discuss your individual prognosis based on all these considerations.^[14]

#1 Clinical Trials Search in Europe